The Play On ADMA Biologics: A Discounted Stock With Good Prospects
Summarize this article with:
Bret JensenInvesting Group LeaderFollow5ShareSavePlay(6min)CommentsSummaryADMA Biologics, Inc. projects EPS to quadruple by 2030, supported by strong revenue growth and margin expansion.ADMA's Q3 results exceeded revenue expectations, with adjusted EBITDA up 29% and FY2025/2026 guidance raised.A recently approved manufacturing process is set to improve yields by 20%, boosting future ADMA margins and profits. Memorystockphoto/iStock via Getty Images I am circling back ADMA Biologics (ADMA) I last looked at this intriguing biotech concern in early August following Q2 results. I am revisiting ADMA Biologics as the company posted Q3This article was written byBret Jensen54.84K FollowersFollowBret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ADMA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You